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Abstract
OBJECTIVE: To investigate the antiepileptic effects
of Chaihushugan decoction (CHSGD) in rats with
pentylenetetrazole (PTZ)-induced seizures and to
discuss the impact of CHSGD on glutamate metab-
olism, a hypothesized underlying mechanism of sei-
zure reduction.
METHODS: Fifty Wistar rats were divided randomly
into either control (n = 10) or experimental (n = 40)
groups. Rats in the control group were adminis-
tered physiological saline intraperitoneally. A sub-
convulsive dose of PTZ (35 mg/kg) was adminis-
tered intraperitoneally to rats in the experimental
group to induce seizures. The fully PTZ-kindled rats
were then randomly divided into five subgroups
(n = 8 each) based on the following treatment cate-
gories: physiological saline, VPA (200 mg/kg), CHS-
GD (2.5 g/kg), CHSGD (5 g/kg), or CHSGD (10 g/kg),
administered orally once per day, respectively. On
day 28 following initiation of drug treatment, sei-
zures were monitored. The rats were then sacri-
ficed, and hippocampal dissections were per-
formed for subsequent studies.
RESULTS: CHSGD significantly prolonged the laten-
cy of myoclonic, clonic, and tonic seizures, while de-
creasing overall seizure rates in the kindled rats.
The measured concentrations of 2-[N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-glucose
(2-NBDG) and glutamate were significantly lower in
the hippocampi of kindled rats in groups treated
with CHSGD compared with those treated with PTZ
alone. In addition, CHSGD was found to up-regu-
late both the expression of glutamate transporter-1
(GLT-1) protein and the activity of glutamine syn-
thetase (GS) in the hippocampi of kindled rats.
CONCLUSION: These results suggest that CHSGD
has antiepileptic effects on PTZ-induced seizures.
The results further suggest an increase in gluta-
mate metabolism at the synaptic cleft is a putative
underlying mechanism of seizure reduction.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Epilepsy is one of the most common neurological disor-
ders, with a prevalence of approximately 0.3%-0.5%.1
It is well recognized that epileptic seizures are caused
by a sudden imbalance between excitatory and inhibito-
ry signals in the brain, involving the major neurotrans-
mitters glutamate and gamma-aminobutyric acid (GA-
BA). Glutamate is the most significant excitatory neu-
rotransmitter in the mammalian central nervous sys-
tem (MCNS). However, excessively high extracellular
concentrations of glutamate have a tendency to result
in excitotoxic neuronal death. Studies of the brains of
patients with temporal lobe epilepsy using in vivo mi-
crodialysis have shown that the extracellular glutamate
concentration rises in the sclerotic hippocampus just
before a seizure, and remains elevated for at least 15 min
following the cessation of electrographic seizure activi-
ty.2
Although quite a few antiepileptic drugs (AEDs) are
available for treatment, their use is limited by adverse
effects and the susceptibility for drug-drug interac-
tions.3,4 It therefore remains a challenge to treat epilep-
sy with a high degree of efficacy while reducing poten-
tially adverse effects. Traditional Chinese Medicine has
long been used to treat epilepsy. Chaihushugan decoc-
tion (CHSGD) is a combination of two classical Chi-
nese prescriptions: Xiaochaihu Tang and Guizhi Tang.
These prescriptions originate from Shang Han Lun,5 a
famous doctor in the Han Dynasty of China. In a pre-
vious clinical study, we found that CHSGD could ef-
fectively inhibit epilepsy.6 We also found that CHSGD
demonstrated antiepileptic activities in a variety of in
vivo acute-seizure models including the pentylenetetra-
zole (PTZ)-convulsion, maximal-electroshock (MES)
and strychnine-induced acute-seizure models. In the
Li-pilocarpine induced refractory-epilepsy model,
CHSGD reduced the durations and stage of seizures.7
In addition, CHSGD decreased the expression of the
multidrug-resistance protein P-glycoprotein in the hip-
pocampus and the temporal cortex of rats with Li-pilo-
carpine-induced refractory epilepsy.8 The precise antiep-
ileptic mechanism of CHSGD, however, is still un-
known.
In the present study, the PTZ kindling model was used
to further evaluate the antiepileptic effects of CHSGD.
Additionally, we investigated whether CHSGD modu-
lates the glutamate metabolism pathway to determine
the underlying mechanism of its antiepileptic effects.
MATERIALS ANDMETHODS
Animals
Fifty male 12-week-old Wistar rats of (specific-patho-
gen-free grade, 180-220 g), purchased from the Experi-
mental Animal Center of Southern Medical University,
Guangzhou, China (Certificate of quality No. SCXK
[yue] 2006-0015), were used in this study. The rats
were housed under constant temperature (23 ± 1 ℃ )
and humidity (60% ± 10%), with a 12 h light/dark cy-
cle (lights on from 07:00 to 19:00). All animal treat-
ment and maintenance procedures were conducted in
accordance with the guidelines of the Institutional Ani-
mal Care and Use Committee of Southern Medical
University, Guangzhou, China.
Reagents
The reagent 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
amino]-2-deoxy-d-glucose (2-NBDG) was purchased
from Invitrogen Corporation (Invitrogen Corporation,
Carlsbad, CA, USA). Rabbit anti-EAAT2 antibodies
were obtained from Abcam (Cambridge, UK). Mouse
anti-β-actin polyclonal antibodies, goat anti-rabbit
IgG-HRP and goat anti-mouse IgG-HRP were pur-
chased from Beyotime (Beyotime, Shanghai, China).
The GS kit was obtained from Nanjing Jiancheng Bio-
engineering Institute (Jiancheng, China). PTZ and all
other reagents were purchased from Sigma (St. Louis,
MO, USA).
Preparation of CHSGD
The CHSGD used in this study consisted of 15 Chi-
nese herbs: Chaihu (Radix Bupleuri Chinensis),
Huangqin (Radix Scutellariae Baicalensis), Banxia (Rhi-
zoma Pinelliae), Dangshen (Radix Codonopsis), Guizhi
(Ramulus Cinnamomi), Baishao (Radix Paeoniae Alba),
Danggui (Radix Angelicae Sinensis), Chuanxiong (Rhi-
zoma Chuanxiong), Dihuang (Radix Rehmanniae),
Longgu (Os Draconis), Muli (Concha Ostreae),
Gouteng (Ramulus Uncariae Rhynchophyllae cum Un-
cis), Dazao (Fructus Jujubae), stir-frying with liquid ad-
juvant Gancao (Radix Glycyrrhizae) and Shengjiang
(Rhizoma Zingiberis Recens). The dried herbs were pur-
chased from the pharmacies of Nan Fang hospital and
the First Affiliated Hospital of Southern Medical Uni-
versity. The herbs were authenticated by the pharma-
cognosy expert at the Department of Pharmacognosy,
China Pharmaceutical University, China. The herbs
were then mixed at a ratio (in the order previously
mentioned) of 25∶10∶10∶10∶10∶10∶10∶10∶10∶30∶
30∶15∶10∶10∶10 (dry weight). The herbs were im-
mersed in water for 30 min and then decocted in boil-
ing water for 2 h. We centrifuged the extract at 1.5 ×g
at room temperature. The suspension was concentrated
in a rotary evaporator. The yield of dried extract from
the starting crude material was estimated to be
56.37%. The extracts were stored at 4 ℃ and dissolved
in distilled water before use.9 Valproic acid (VPA) was
used as a positive control drug.
Pentylenetetrazole kindling
PTZ kindling was performed according to the proce-
dures described previously.10 Fifty Wistar rats were ran-
domly divided into either control (n = 10) or experi-
mental (n = 40) groups. Rats in the control group were
intraperitoneally administered physiological saline.
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Rats in the experimental group were injected with a
sub-convulsive dose of PTZ (35 mg/kg, intraperitoneal-
ly) three times per week (Monday, Wednesday and Fri-
day). After each injection, the rats were placed in isolat-
ed cages and were observed for 30 min. Seizure activity
was evaluated according to Racine's criteria:11 stage 0,
no behavioral changes; stage 1, ear and facial twitch-
ing; stage 2, myoclonic convulsions without rearing;
stage 3, myoclonic convulsions with rearing; stage 4,
clonic convulsions with loss of posture; stage 5, supine
orientation with generalized tonic-clonic seizures. Ani-
mals with two consecutive stage 5 seizures were consid-
ered to be fully kindled and were used for further ex-
periments.
Subgrouping the treatment group and their
treatments
Fully-PTZ-kindled rats (n = 40) were randomly divid-
ed by a number table method into five subgroups
based on the following treatment categories (n = 8
each): PTZ (treated with an equivalent volume of phys-
iological saline), PTZ plus VPA (200 mg/kg), PTZ
plus CHSGD (2.5 g/kg), PTZ plus CHSGD (5 g/kg),
and PTZ plus CHSGD (10 g/kg), administered orally
once per day for 28 days, respectively. On day 28, 1 h
following final treatment administration, the experi-
mental rats were injected once more with PTZ (35 mg/
kg). The latency to myoclonic convulsions, clonic con-
vulsions, and generalized tonic-clonic seizures was ob-
served. The seizure stage and numbers of myoclonic
convulsions, clonic convulsions and generalized ton-
ic-clonic seizures were also evaluated. Following behav-
ioral observation, the rats were anesthetized with sodi-
um barbital, sacrificed, and their brain tissues were sep-
arated under sterile conditions. The hippocampi were
dissected bilaterally and stored at − 80 ℃ for further
evaluation.
Fluorescent imaging assay of 2-[N-(7-nitrobenz- 2-
oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-glucose (2-NB-
DG)
Fluorescent imaging using 2-NBDG was performed to
evaluate the hippocampal neuronal excitability of kin-
dled rats.12 On day 28 following initiation of treat-
ment, 2-NBDG (2 mL, 1%) was injected into the tail
veins of kindled rats. The injection was administered
in a continuous manner to prolong circulation time
and allow 2-NBDG to reach brain cells. After 30 min,
PTZ was injected into rats. Following behavioral evalu-
ation, the rats were anesthetized with sodium barbital.
Rat brains were separated, and 500-μm-thick coronal
slices were cut using a freezing microtome. Fluorescent
images of coronal slices were captured using light absor-
bance and emission wavelengths of 475 and 550 nm,
respectively, with an exposure time of 10 s. The concen-
trations of 2-NBDG in the hippocampi of experimen-
tal rats were determined by normalizing the average flu-
orescence intensity in the hippocampus to that of the
whole brain.
Evaluation of hippocampal glutamate
concentrations by high performance liquid
chromatography (HPLC)
Quantitative determination of glutamate in the hippo-
campi of experimental rats was carried out using the
HPLC method, as previously described,13 using
O-phthaldialdehyde (OPA) derivatization and a fluores-
cence detector.14 Briefly, hippocampal tissue samples
were homogenized in 2 mL of 80% ethyl alcohol at
4 ℃. After the homogenate was centrifuged, the super-
natant was completely removed by evaporation, and
the dried sample was frozen. Pelleted hippocampal sam-
ples were then dissolved in a 0.1 mol/L HCL solution
(Sigma, St. Louis, MO, USA) using ultrasonic vibra-
tion (1000 W) at 37 ℃ for 1 h. The dissolved mixture
was transferred to a 5-mL container, centrifuged (15
000 rpm, 4 ℃ ), and the supernatant was filtered
through a 0.45-μm-membrane filter (Millipore, Billeri-
ca, MA, USA). Two 1-μL filtrate samples were added
to a 4-μL internal standard, derivatized with 13 μL
OPA, and injected onto an HPLC column (Hypersil
ODS Column, 4.0 mm× 125 mm, 5 μm). The HPLC
fluorescence detector was set for absorbance at 340 nm
and emission at 450 nm. Peak areas of glutamate were
compared with standards to determine the relative con-
centrations in the samples. The concentrations of gluta-
mate in the hippocampi of experimental rats were ex-
pressed as μmol/g of fresh tissue.
Western blot analysis for glutamate transporter-1
(GLT-1)
Hippocampal tissue samples were homogenized using
an Ultraturrax (Janke & Kunkel, Staufen, Germany) at
4 ℃ in lysis buffer (pH 7.5, 50 mmol/L Tris-HCl, 150
mmol/L NaCl, 10% glycerol, 1% Nonidet P-40, 0.1%
sodium dodecyl sulfate (SDS), 0.5% deoxycholate,
100 mg/L phenyl methyl sulfonyl fluoride, and 100
mmol/L sodium orthovanadate; Beyotime, Shanghai,
China) for 30 min. The homogenized lysates were cen-
trifuged three times at 20 000 × g at 4 ℃. The superna-
tants of lysates were used for subsequent measure-
ments. Protein contents of hippocampal lysates were
determined using the Enhanced BCA Protein Assay
Kit (Beyotime, Shanghai, China), using bovine serum
albumin as a standard. Samples were mixed with sam-
ple buffer (pH 6.8, 4% SDS, 20% glycerol, and 125
mmol/L Tris- HCl), boiled for 5 min for denaturation,
and then subjected to 10% SDS-polyacrylamide gel
electrophoresis. Proteins were then transferred to poly-
vinylidene difluoride membranes (PVDF, Millipore,
Billerica, MA, USA) using a semi-dry transfer appara-
tus (Bio-rad, California, USA). The membranes were
blocked with 5% non-fat milk at 37 ℃ for 1.5 h, and
then incubated with anti-GLT-1 antibodies (1∶1000 di-
lution) at 4 ℃ overnight. Membranes were then incu-
bated with horseradish-peroxidase-coupled an-
ti-mouse-IgG antibodies (1∶400 diluted; Beyotime,
Shanghai, China) at room temperature for 2 h and de-
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veloped using an Enhanced Chemiluminescence
(ECL) kit (Beyotime, Shanghai, China). Integrated op-
tical densities of immunoreactive protein bands were
performed using a Kodak Image Station 2000 MM
with Kodak MI software (Eastman Kodak, Rochester,
USA). GLT-1 protein levels were normalized to that ofβ-Actin.
Evaluation of GS activity
GS activity was assayed by the method described by Sa-
dasivudu.15 Briefly, hippocampal tissue samples were
homogenized and centrifuged, followed by determina-
tion of protein concentrations. As specified by the
GS-kit instructions, 50 μL homogenate supernatant
was incubated with 450 μL reaction mixture (consist-
ing of 60 mmol/L L-glutamine, 20 mmol/L Na-arse-
nite, 0.4 mmol/L adenosine diphosphate, 3 mmol/L
MnCl2, and 60 mmol/L imidazole-HCl buffer, pH
6.8, in a final volume of 1 mL) at 37 ℃ in a thermo-
stat-controlled water bath for 15 min. The reaction
was terminated by adding 200 μL of the stop solution
(containing 0.2 mmol/L trichloroacetic acid, 0.67 mol/
L HCl, and 0.37 mol/L FeCl3) for 10 min. After cen-
trifugation at 15 000 × g for 3 min at 4 ℃, the extinc-
tion coefficient of L-γ-glutamyl-hydroxamate (which
formed in the supernatant) was measured at a wave-
length of 500 nm using a 201-Microplate Reader (Sig-
ma, St. Louis, MO, USA). A standard row was created
using γ-glutamyl-hydroxamate. GS activity was ex-
pressed as U/mg protein.
Statistical analysis
Quantitative data were expressed as mean ± standard
deviation ( xˉ ± s), with the exception of seizure rates.
Seizure rates were analyzed using the χ2 test, while a
one-way analysis of variance (ANOVA) followed by the
Least significant difference test was used to test for dif-
ferences between groups. Statistical analyses were per-
formed using SPSS 13.0 software (Statistical Package
for the Social Sciences, Chicago, IL, USA). Signifi-
cance levels were set at P < 0.05.
RESULTS
Effect of CHSGD on PTZ-induced seizures
The onset latencies of myoclonic, clonic, and tonic sei-
zures, along with the percentages of animals presenting
with seizures were determined following treatment
with CHSGD to assess the subsequent effects. Relative
to the PTZ group, groups treated with CHSGD had
significantly higher latencies to myoclonic seizures
[(68.5 ± 4.8) s, PTZ group; (134.3 ± 4.9), (161.3 ±
5.7), and (190.6 ± 3.5) s for groups treated with 2.5, 5
and 10 g/kg CHSGD, respectively; all P < 0.05]. The
rates of rats presenting with myoclonic seizures were
87.5% , 75% and 62.5% for the 2.5, 5, and 10 g/kg
treatment groups, respectively. Compared with the
PTZ group, the latency to clonic seizures was signifi-
cantly higher in the CHSGD-treated groups [(115.6 ±
10.5) s, PTZ group; (167.0 ± 9.9), (210.0 ± 9.5), and
(241.0 ± 13.1) s at 2.5, 5 and 10 g/kg CHSGD, respec-
tively; all P < 0.05]. The rates of rats presenting with
clonic seizures were 75%, 62.5% and 25%, respective-
ly. The latency to tonic seizures was significantly higher
in the PTZ group [(133.1 ± 5.6) s] compared with
CHSGD groups [(280.0 ± 6.3), (304.7 ± 8.5), and
(338.5 ± 3.5) s at doses of 2.5, 5 and 10 g/kg, respec-
tively; all P < 0.05]. The rates of tonic seizures in the
CHSGD groups were significantly lower than in the
PTZ group (100% compared with 38.5% , 27% and
18.5% at 2.5, 5, and 10 g/kg CHSGD, respectively; all
P < 0.05).
Effect of CHSGD on hippocampal concentrations of
2-NBDG in PTZ-kindled rats
The concentrations of 2-NBDG in the hippocampi of
experimental rats in the PTZ group were significantly
higher than those in the control group (Figure 1). Rats
in the CHSGD-treated groups had significantly lower
hippocampal concentrations of 2-NBDG than
PTZ-kindled rats. Concentrations of 2-NBDG (nor-
malized to the control group) were 124.6% ± 6.9% in
the PTZ group compared with 114.4% ± 5.7% ,
109.1% ± 4.5%, and 104.6% ± 4.3% at CHSGD dos-
es of 2.5, 5, and 10 g/kg, respectively (all P < 0.05).
Effect of CHSGD on hippocampal glutamate
concentrations in PTZ-kindled rats
Compared with the control group, the mean concentra-
tion of glutamate in the PTZ group was significantly
higher. Following 28 days of treatment, rats adminis-
tered CHSGD had significantly lower hippocampal
concentrations of glutamate [(7.3 ± 0.1), (7.0 ± 0.2)
and (6.6 ± 0.3) μmol/g at doses of 2.5, 5, and 10 g/kg
CHSGD, respectively] than those receiving saline
[PTZ group, (7.7 ± 0.2) μmol/g; all P < 0.05].
Effect of CHSGD on hippocampal expression of
GLT-1 protein in PTZ-kindled rats
The expression of GLT-1 protein in the hippocampi of
experimental rats was visibly lower in the PTZ group
compared with the control group (Figure 2A). Rats
treated with CHSGD had significantly higher hippo-
campal expression of the GLT-1 protein than those in
the PTZ group (Figure 2B). Additionally, CHSGD
treatment appeared to affect GLT-1 expression in a
dose-dependent manner: normalized to the control
group, rats in the PTZ group had GLT-1 expression
levels of 60.1% ± 1.1% , compared with 62.3% ±
1.1% , 79.1% ± 1.7% , and 91.9% ± 1.1% for those
treated with 2.5, 5, and 10 g/kg CHSGD, respectively
(Figure 2B).
Effect of CHSGD on hippocampal GS activity in
PTZ-kindled rats
Compared with controls, GS activity in the hippocam-
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pi of PTZ-kindled rats was significantly lowered to
79.6%± 4.9% (normalized to the control group) in the
PTZ group. CHSGD treatment resulted in significant-
ly higher hippocampal GS activity in PTZ-kindled rats
compared with those in the PTZ group (86.5% ±
5.4%, 91.2% ± 1.2% and 96.0% ± 3.6% at doses of
2.5, 5, and 10 g/kg, respectively; all P < 0.05).
DISCUSSION
In the present study, we found that CHSGD adminis-
tration with for 28 days, significantly delayed the ap-
pearance of myoclonic, clonic, and tonic seizures, and
reduced the seizure stage. Additionally, CHSGD treat-
ment affected the rates of myoclonic, clonic, and tonic
seizures of PTZ-kindled rats in a dose-dependent man-
ner. These results provide further evidence indicating
that CHSGD has anticonvulsant properties.
The localization of neuronal activity, especially during
epileptic seizures, is of great importance to our current
understanding of neurophysiology. Blood flow, overall
metabolic rate, and flux through glycolysis and the tri-
carboxylic acid cycle are all increased in the brain as a
result of the heightened ATP demand during seizures.16
Perfusion-based brain imaging, which relies on the cou-
pling between neuronal excitability and glucose metab-
olism, has become a popular method to localize epilep-
tic foci.17 In the present study, we evaluated glucose me-
tabolism in the brains of PTZ-kindled rats using 2-NB-
DG, a fluorescent analogue of D-glucose. After a slow,
continuous injection of 2-NBDG, a subconvulsive
dose of PTZ (35 mg/kg) was again injected into
PTZ-kindled rats. Following this injection, the concen-
tration of 2-NBDG clearly increased in the hippocam-
pus of epileptic rats. These results suggest that glucose
metabolism was increased in the brains of rats follow-
ing PTZ-kindling. These data are in accordance with
previous studies showing a clear increase in energy de-
mand following PTZ-kindling and demonstrating that
epileptic activity increases glucose transport in neu-
rons.18 The increases in hippocampal levels of 2-NB-
DG in PTZ-kindled rats were significantly attenuated
following CHSGD treatment for 28 days. These data
suggest that CHSGD can inhibit neuronal hyperexcit-
ability in PTZ-kindled rats.
Neuronal hypermetabolism associated with seizures
was found to be coupled with abnormally elevated
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Figure 2 Effect of CHSGD on hippocampal GLT-1 protein ex-
pression in PTZ-kindled rats
A: blots of GLT-1 protein expression in each group. B: bar
graph showing the expression of the GLT-1 protein in the
hippocampus of the experimental rats in each group. 1: PTZ
+ VPA; 2: PTZ; 3: normal; 4: PTZ + CHSGD 2.5 g/kg; 5: PTZ +
CHSGD 5 g/kg; 6: PTZ + CHSGD 10 g/kg. PTZ group was
treated with normal saline. PTZ + VPA group was treated
with VPA 200 mg/kg. PTZ + CHSGD 2.5 g/kg group was treat-
ed with CHSGD 2.5 g/kg. PTZ + CHSGD 5 g/kg group was
treated with CHSGD 5 g/kg. PTZ + CHSGD 10 g/kg group
was treated with CHSGD 10 g/kg. CHSGD: Chaihushugan de-
coction; PTZ: pentylenetetrazole; VPA: valproic acid; GLT-1:
glutamate transporter-1. The results are expressed as the
mean ± standard deviation (n = 8). aP < 0.05, compared with
the PTZ group.
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Figure 1 Fluorescent images of 2-NBDG in the hippocampus of the experimental rats in each group
A: control; B: PTZ; C: PTZ + VPA; D: PTZ + CHSGD 2.5 g/kg; E: PTZ + CHSGD 5 g/kg; F: PTZ + CHSGD 10 g/kg. PTZ group was treated
with normal saline. PTZ + VPA group was treated with VPA 200 mg/kg. PTZ + CHSGD 2.5 g/kg group was treated with CHSGD
2.5 g/kg. PTZ + CHSGD 5 g/kg group was treated with CHSGD 5 g/kg. PTZ + CHSGD 10 g/kg group was treated with CHSGD
10 g/kg. CHSGD: Chaihushugan decoction; PTZ: pentylenetetrazole; VPA: valproic acid; 2-NBDG: 2-[N-(7-nitrobenz-2-oxa-1, 3-dia-
zol-4-yl) amino]-2-deoxy-d-glucose.
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levels of extracellular glutamate.19 Excessive extracellu-
lar glutamate, which has long been associated with
increased likelihood of seizures, is strongly linked
with upregulation of glycolysis and hyper-excitability
in neurons.16
Previously published data indicated that the mecha-
nism underlying PTZ-induced seizures was directly
linked to an increase in the release of excitatory amino
acids (glutamate and aspartate) during seizures, interic-
tal periods, and the early phase of the PTZ-kindling.20
In this study, we observed significant changes in the
hippocampal glutamate levels of PTZ-kindled rats fol-
lowing administration of CHSGD. The concentrations
of glutamate measured from samples obtained 30 min
after the final injection of a subconvulsive dose of PTZ
were significantly lower in PTZ-kindled rats that re-
ceived treatment with CHSGD. These results suggest
that the inhibitory effects of CHSGD on the neuronal
hyperexcitability of PTZ-kindled rats may be caused
by a resulting decrease in the concentration of extracel-
lular glutamate.
Extracellular glutamate concentrations in the MCNS
are maintained at a low level (primarily via astrocytes)
to prevent neurotoxicity caused by excessive activation
of glutamate receptors. Glutamate released at the syn-
apse is normally taken up by astrocytes through
high-affinity, sodium-dependent glutamate transport-
ers, where it is rapidly converted to the non-excitotoxic
amino acid glutamine via the enzyme GS. Following
synthesis, glutamine is transported back to neurons,
where it can then be converted to glutamate, mainly
via the phosphate-activated enzyme glutaminase. This
process of transport and conversion is referred to as glu-
tamine-glutamate cycling (GGC).21 Studies have
shown that GGC is disrupted in the hippocampus of
brains affected by temporal lobe epilepsy.22 GLT-1 is
the primary astrocytic transporter and is responsible
for 90% of total glutamate uptake. In the absence of
functional GLT-1, glutamate levels rise to levels suffi-
cient to cause epilepsy and cell death.23 It has been re-
ported that GLT-1-knock-out mice exhibit spontane-
ous seizures.24 GS is the key rate-limiting enzyme in
the relatively rapid metabolism of intracellular gluta-
mate. The inhibition of GS by systemic administration
of methionine sulfoximine readily causes seizures in
rats and mice.25 Studies have shown that GS protein ex-
pression and activity in the hippocampal formation is
significantly lower in patients with temporal lobe epi-
lepsy than in non-epilepsy control subjects.26
In this study, we found that the expression of GLT-1
protein and activity of GS are both lower in the hippo-
campi of PTZ-kindled rats. This is in accordance with
the findings of previous studies, which indicated that
the levels of GLT-1 and GS were decreased following
PTZ-induced seizures.27,28 CHSGD significantly attenu-
ated the decreases in expression of GLT-1 protein and
activity of GS in the hippocampi of PTZ-kindled rats,
resulting in an increase in glutamate metabolism in the
brains of PTZ-kindled rats.
In summary, the results of this study show that the Chi-
nese herbal prescription CHSGD had anticonvulsant
effects on PTZ-induced kindled seizures. We also pro-
vide evidence that CHSGD exerts its observed antiepi-
leptic effects by increasing glutamate metabolism at the
synaptic cleft, and ultimately reducing neuronal hyper-
excitability.
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